Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 5/20 | 0.68 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.68 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.68 |
| ▸ | TSHR | P16473 | 1/20 | 0.68 |
| ▸ | HTR2A | P28223 | 1/20 | 0.68 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.68 |
| ▸ | FBP1 | P09467 | 9/20 | 0.55 |
| ▸ | PPARG | P37231 | 5/20 | 0.48 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | PPARD | Q03181 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5892279 | 0.94 | PPARA (0.68) | PPARAABCB11CYP1A2CYP3A4TSHR | |
| SCHEMBL13905182 | 0.88 | PPARA (0.68) | PPARAABCB11CYP1A2CYP3A4TSHR | |
| SCHEMBL5892213 | 0.87 | PPARA (0.57) | PPARAABCB11CYP1A2CYP3A4TSHR | |
| SCHEMBL3683041 | 0.85 | PPARA (0.64) | PPARAABCB11CYP1A2CYP3A4TSHR | |
| SCHEMBL5892237 | 0.85 | PPARA (0.48) | PPARAABCB11CYP1A2CYP3A4TSHR | |
| SCHEMBL3692605 | 0.83 | PPARA (0.65) | PPARAABCB11CYP1A2CYP3A4TSHR | |
| SCHEMBL5990208 | 0.82 | PPARA (0.59) | PPARAABCB11CYP1A2CYP3A4TSHR | |
| SCHEMBL5892173 | 0.82 | PPARA (0.60) | PPARAABCB11CYP1A2CYP3A4TSHR | |
| Clofibrate SCHEMBL2356 | 0.81 | PPARA (1.00) | PPARAABCB11CYP1A2CYP3A4TSHR | |
| SCHEMBL5727212 | 0.81 | PPARA (0.62) | PPARACYP1A2CYP3A4TSHRPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7071221-B2 | Heterocyclic oxime compounds | LES LABORATOIRES SERVIER (FR) | 2006-07-04 | — | — | US | disclosed |
| US-20050026973-A1 | New heterocyclic oxime compounds | LES LABORATOIRES SERVIER (FR) | 2005-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050026973-A1 | New heterocyclic oxime compounds | CBR3, CBR1, CYB5R3 | PPARA 1112/4885ABCB11 3738/4885CYP1A2 133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.